A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if SU011248 (sunitinib) provides additional benefit when it is given after treatment with two chemotherapy drugs carboplatin and paclitaxel and also if sunitinib is safe for patients with locally advanced and metastatic Non Small Cell Lung Cancer (NSCLC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Carboplatin; Paclitaxel; Sunitinib

Criteria

Inclusion Criteria:

• Histologically proven NSCLC

• Stage IIIB (locally advanced with malignant effusion) or Stage IV disease

• No prior therapy for NSCLC

• Evidence of unidimensionally measurable disease

Exclusion Criteria:

• Previous treatment with systemic chemotherapy for lung cancer

• History of or known brain metastases

• NCI CTCAE Grade 3 hemorrhage within 4 weeks of starting study treatment

• Evidence of hemoptysis within 4 weeks of starting study treatment

• Serious acute or chronic illness or recent history of significant cardiac abnormality

• Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of EGFR and PDGFR